Esperion to Report First Quarter 2026 Financial Results on May 7
Rhea-AI Summary
Esperion (NASDAQ: ESPR) will report first quarter 2026 financial results before the market opens on May 7, 2026.
Management will host a live webcast at 8:00 a.m. ET the same day to discuss results and business updates; a replay will be available about two hours after the call and archived for ~90 days.
Positive
- None.
Negative
- None.
News Market Reaction – ESPR
In the Apr 23 session, ESPR declined 3.05%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings date notice | Neutral | -1.2% | Scheduled Q4 and full-year 2025 results with webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history: one prior earnings-date announcement saw a small -1.2% move, suggesting modest reactions to such scheduling news.
Over recent months, ESPR has reported several cardiometabolic and strategic milestones, including CLEAR Outcomes analyses, new ACC/AHA guideline recommendations for bempedoic acid, and the Corstasis acquisition. Against this backdrop, the latest item is a routine notice that Q1 2026 results will be released on May 7, 2026 with an accompanying webcast. The only prior earnings date release on Feb 24, 2026 (for Q4 and full-year 2025) prompted a modest -1.2% move, indicating historically muted responses to similar announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
